title: Role of glucagon-like peptide 1 receptor agonists in management of obesity.
abstract: OBJECTIVE
  Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists are reviewed, with a focus on data from clinical trials.
  
  
  CONCLUSIONS
  Obesity is a significant health problem in the United States (an estimated 69% of U.S. adults are overweight and nearly 35% are obese), and few drugs have proven safety and efficacy as adjuncts to lifestyle modification for weight management. GLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes and have been studied for their weight loss effects in patients with and without diabetes; these agents produce weight loss benefits through their effects on satiety and gastric emptying. In December 2014, the liraglutide product Saxenda (Novo Nordisk) became the first GLP-1 receptor agonist approved by the Food and Drug Administration (FDA) for use in long-term weight management. Results of clinical trials that evaluated the effects of GLP-1 receptor agonist therapy on weight and body mass index indicated outcomes comparable or superior to those achieved with the use of other antiobesity agents. As a class, GLP-1 receptor agonists have a generally more favorable safety profile than several other antiobesity agents; transient, mild-to-moderate gastrointestinal symptoms were the most frequently reported adverse effects in clinical trials.
  
  
  CONCLUSIONS
  Originally marketed for glycemic control in type 2 diabetes, GLP-1 receptor agonists have been found effective for weight reduction in patients with and without type 2 diabetes. Liraglutide is currently the only GLP-1 receptor agonist approved by FDA for obesity treatment.
authors: Chicago State University, Chicago, ILOak Lawn VA Clinic of Edward Hines Jr. VA Hospital, Oak Lawn, IL. dianamisaacs@gmail.com.
authors: Diana
authors: D
authors: Isaacs
authors: Chicago State University, Chicago, ILRush University Medical Center, Chicago, IL.
authors: Lalita
authors: L
authors: Prasad-Reddy
authors: Chicago State University, Chicago, ILACCESS Community Health Network, Chicago, IL.
authors: Sneha Baxi
authors: SB
authors: Srivastava
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008019:Life Style; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D015995:Prevalence; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D015431:Weight Loss / Q000187:drug effects; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D004763:Glucagon-Like Peptides; D000097789:Glucagon-Like Peptide-1 Receptor Agonists